LIFE Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

18.990

Open

18.750

VWAP

19.00

Vol

957.00K

Mkt Cap

131.00M

Low

18.220

Amount

18.00M

EV/EBITDA(TTM)

--

Total Shares

--

EV

-23.00M

EV/OCF(TTM)

--

P/S(TTM)

316.00

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Show More

Events Timeline

(ET)

2026-01-29

10:20:00

New

Ethos Prices 10.526M Shares at $19.00

2026-01-29

06:20:00

Goldman Sachs and Others Manage IPO Deal Range of $18-$20

2026-01-20 (ET)

2026-01-20

11:20:00

Goldman Sachs and Five Banks Jointly Manage New Offering

2026-01-07 (ET)

2026-01-07

08:31:00

Ethos Partners with North American Company to Launch New IUL Product

2025-12-18 (ET)

2025-12-18

08:20:00

Ethos Partners with Aflac to Expand Insurance Offerings

News

an image of seekingalpha

15:11 PMseekingalpha

Ethos Technologies IPO Raises $97.4 Million at $19 per Share

an image of renaissancecapital

14:08 PMrenaissancecapital

Ethos Technologies Raises $200 Million in IPO, Valued at $1.3 Billion

an image of renaissancecapital

01-24renaissancecapital

York Space Systems (YSS) Plans to Raise $512 Million at $4 Billion Market Cap

an image of seekingalpha

01-20seekingalpha

Ethos Technologies (LIFE) Files for IPO of ~5.13M Shares at $18-$20 Each

an image of renaissancecapital

01-20renaissancecapital

Ethos Technologies Plans $200 Million IPO with $1.3 Billion Valuation

an image of renaissancecapital

01-10renaissancecapital

Multiple Companies Poised for IPO Launches This Week

0 Analyst Rating

Wall Street analysts forecast LIFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIFE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

KeyBanc

Steve Dechert

maintain

AI Analysis

2026-01-08

Reason

KeyBanc

Steve Dechert

Price Target

AI Analysis

2026-01-08

maintain

Reason

KeyBanc analyst Steve Dechert raised the firm's price target on LifeStance to $8.50 from $6.50 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.

Citizens

Outperform -> Market Perform

downgrade

$NULL

2026-01-05

Reason

Citizens

Price Target

$NULL

2026-01-05

downgrade

Outperform -> Market Perform

Reason

Citizens downgraded Life360 to Market Perform from Outperform without a price target. The company's core growth has slowed recently, and Citizens is now "more skeptical" of its 2026 catalysts, the analyst tells investors in a research note. The firm says Life360 will lap a successful U.S. advertising campaign in 2026, while its U.S. price increases are also likely more limited until the company releases another major feature update.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LIFE

Unlock Now

Valuation Metrics

The current forward P/E ratio for aTyr Pharma Inc (LIFE.O) is , compared to its 5-year average forward P/E of . For a more detailed relative valuation and DCF analysis to assess aTyr Pharma Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding LIFE

Trading Trends

People Also Watch

Frequently Asked Questions

What is aTyr Pharma Inc (LIFE) stock price today?

The current price of LIFE is 18.37 USD — it has decreased -3.32 % in the last trading day.

What is aTyr Pharma Inc (LIFE)'s business?

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

What is the price predicton of LIFE Stock?

Wall Street analysts forecast LIFE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIFE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is aTyr Pharma Inc (LIFE)'s revenue for the last quarter?

aTyr Pharma Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is aTyr Pharma Inc (LIFE)'s earnings per share (EPS) for the last quarter?

aTyr Pharma Inc. EPS for the last quarter amounts to -0.23 USD, increased 15.00 % YoY.

How many employees does aTyr Pharma Inc (LIFE). have?

aTyr Pharma Inc (LIFE) has 56 emplpoyees as of January 29 2026.

What is aTyr Pharma Inc (LIFE) market cap?

Today LIFE has the market capitalization of 131.00M USD.